乌罗立-A通过FOXO1激活促进CD8+T细胞介导的癌症免疫监测
Pierpaolo Ginefra1, Helen Carrasco Hope1, Yi-Hsuan Chiang1
1Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Lausanne, Switzerland.
Cancer research communications
|April 16, 2024
概括
乌罗立-A通过激活CD8+ T细胞中的FOXO1转录因子来增强癌症免疫监测. 这促进了原始T细胞的扩张,改善了对癌症的免疫反应.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 原始的T细胞对于癌症免疫监测至关重要,但在瘤进展过程中会下降.
- 需要进行干预,以维持原始的T细胞功能,以改善癌症免疫预防.
研究的目的:
- 调查乌罗立-A增强T细胞介导癌症免疫监测的能力.
- 探索Urolithin-A在T细胞中的作用机制.
主要方法:
- 研究了乌罗立-A (UroA) 对T细胞的影响.
- 分析了CD8+ T细胞中转录因子FOXO1的激活.
- 评估了L-选择素 (CD62L) 和T细胞种群的表达.
主要成果:
- 在CD8+ T细胞中激活了Urolithin-A的FOXO1.
- FOXO1激活导致L-选择素表达增加和原始T细胞扩张.
- 乌罗立A降低了FOXO1酸化,促进了其核局部化和活性.
结论:
- FOXO1 是 CD8+ T 细胞中 Urolithin-A 的一种新型分子标.
- 乌罗立-A作为一种免疫调节剂,有望增强癌症免疫监测.
- 维持原始的T细胞种群可能会改善癌症免疫预防策略.
相关概念视频
01:27Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K